LATE-BREAKING ABSTRACT: Safety, pharmacokinetics and pharmacodynamics of BI 1060469, a novel oral CRTH2 antagonist

被引：0
|
作者：
Bateman, Eric
Mackie, Alison
Benediktus, Ewald
Schepers, Carnelia
Kim, Jiyeong Maria
Tadayasu, Yusuke
Lee, Ganghyuck
Wood, Chester
Weber, Benjamin
机构：
来源：
EUROPEAN RESPIRATORY JOURNAL | 2016年 / 48卷
关键词：
Asthma; -; management; Inflammation; Pharmacology;
D O I：
10.1183/13993003.congress-2016.PA4125
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
PA4125
引用
收藏
页数：2
相关论文
共 39 条
  • [21] Pharmacodynamics, Pharmacokinetics, and Safety of AM211: A Novel and Potent Antagonist of the Prostaglandin D2 Receptor Type 2
    Bain, G.
    King, C. D.
    Brittain, J.
    Hartung, J. P.
    DeArmond, I.
    Stearns, B.
    Truong, Y. P.
    Hutchinson, J. H.
    Evans, J. F.
    Holme, K.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 52 (10): : 1482 - 1493
  • [22] LATE-BREAKING ABSTRACT: LAVOLTA I and II: Results of 2 phase III studies to assess the efficacy and safety of lebrikizumab in patients with uncontrolled asthma
    Hanania, Nicola
    Korenblat, Phillip
    Chapman, Kenneth R.
    Bateman, Eric D.
    Kopecky, Petr
    Paggiaro, Pier L.
    Yokoyama, Akihito
    Olsson, Julie
    Gray, Sarah
    Holweg, Cecile T. J.
    Eisner, Mark
    Asare, Charles
    Matthews, John G.
    EUROPEAN RESPIRATORY JOURNAL, 2016, 48
  • [23] LATE-BREAKING ABSTRACT: Novel rapid screening assay for HER2 duplicated insertion mutation by Eprobe-PCR method
    Takase, Yoshiaki
    Shimizu, Kimihiro
    Atsumi, Jun
    Enokida, Yasuaki
    Obayashi, Kai
    Ohtaki, Yoichi
    Nagashima, Toshiteru
    Ichihara, Tatsuo
    Kimura, Yasumasa
    Usui, Kengo
    Mitani, Yasumasa
    Takeyoshi, Izumi
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [24] Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers (vol 5, pg 306, 2016)
    Erpenbeck, V. J.
    Vets, E.
    Gheyle, L.
    Osuntokun, W.
    Larbig, M.
    Neelakantham, S.
    Sandham, D.
    Dubois, G.
    Elbast, W.
    Goldsmith, P.
    Weiss, M.
    CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT, 2020, 9 (07): : 889 - 890
  • [25] Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects
    Tarral, A
    Dostert, P
    Guillevic, Y
    Fabbri, L
    Rondelli, I
    Mariotti, F
    Imbimbo, BP
    JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 43 (08): : 901 - 911
  • [26] Late-breaking abstract: The influence of four weeks of beta2-adrenoceptor activation with oral terbutaline on body composition and skeletal muscle contractile properties in active men
    Hostrup, Morten
    Kalsen, Anders
    Haase, Christoffer
    Bangsbo, Jens
    Backer, Vibeke
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [27] Safety, Pharmacokinetics, and Pharmacodynamics of the Novel Oral Peptide Therapeutic PN-10943 (alpha4beta7 Integrin Antagonist) in Normal Healthy Volunteers
    Gupta, Suneel K.
    Cheng, Xiaoli
    Kanwar, Bittoo
    Matheakis, Larry
    Bhandari, Ashok
    Liu, David
    Shames, Rich
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2019, 114 : S431 - S431
  • [28] Single and multiple dose safety, tolerability, pharmacokinetics and pharmacodynamics of PRX-08066, a novel 5-HT2B antagonist.
    Iyer, G. R.
    Milovanovic, J.
    Donahue, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S92 - S92
  • [29] Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
    Teng, Renli
    Butler, Kathleen
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 66 (05) : 487 - 496
  • [30] Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects
    Renli Teng
    Kathleen Butler
    European Journal of Clinical Pharmacology, 2010, 66 : 487 - 496
1234